Obesity Clinical Trials

274 studies are recruiting for obesity in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. Graded Insulin Suppression Test P&F

   The goal of this study is to learn about how the hormone insulin controls blood sugar in a variety of people. The main question it aims to answer is about how much insulin the body actually needs to maintain a normal blood sugar level. Participants will be asked to come in for a one-day study visit…

   Stage

   Phase 1

   Ages

   18 to 65

   Site

   Columbia University Irving Medical Center, New York, New York

   Run by

   Columbia University

   See if you can join NCT06592261 on ClinicalTrials.gov

2. A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

   The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks.

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Prime Medical Group, LLC dba Gilbert Center for Family Medicine, LLC, Gilbert, Arizona

   Locations

   42 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07215559 on ClinicalTrials.gov

3. A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

   The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Birmingham Clinical Research, Birmingham, Alabama

   Locations

   157 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07282600 on ClinicalTrials.gov

4. A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

   The purpose of the studies is to evaluate the efficacy and safety of eloralintide in participants with moderate-to-severe obstructive sleep apnea and obesity or overweight. YDAO is a master protocol designed to support two independent studies: YSA1 and YSA2. Study YSA1 will include participants who…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Cullman Clinical Trials, Cullman, Alabama

   Locations

   115 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07369011 on ClinicalTrials.gov

5. A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

   The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy. Participation in the study will last about 80 weeks.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Birmingham Clinical Research, Birmingham, Alabama

   Locations

   187 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07392190 on ClinicalTrials.gov

6. A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

   The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition and physical activity in adolescents with obesity and multiple weight related comorbidities. The study will last approximately 76 weeks and may inclu…

   Stage

   Phase 3

   Ages

   12 to 17

   Site

   Winterberry Research Inc., Hamilton,

   Locations

   69 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06439277 on ClinicalTrials.gov

7. Effect of Tirzepatide on Markers of MASLD in Patients With Obesity

   Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most common cause of chronic liver disease worldwide and predominately affects individuals with overweight and obesity, as well as those with type 2 diabetes and cardiovascular disease. Tirzepatide is a medication used to treat…

   Stage

   EARLY_Phase 1

   Ages

   18 to 75

   Site

   University of New Mexico Health Sciences Center, Albuquerque, New Mexico

   Run by

   University of New Mexico

   See if you can join NCT06934642 on ClinicalTrials.gov

8. AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

   The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the trea…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Univ of Alabama Birmingham, Birmingham, Alabama

   Locations

   74 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07533175 on ClinicalTrials.gov

9. A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

   The purpose of this clinical study is to learn about the effects and safety of berobenatide (PF-08653944). This may help people with overweight or obesity lose weight. People in this study may also have type 2 diabetes. About 950 adults will be in this study. Berobenatide will be compared to a plac…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   San Fernando Valley Health Institute, Canoga Park, California

   Locations

   50 in total

   Run by

   Pfizer

   See if you can join NCT07595549 on ClinicalTrials.gov

10. A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

    The purpose of this clinical study is to look at how well a study medicine called cagrilintide helps people living with excess body weight to lose weight. Participants will either get cagrilintide, the active study medicine being tested or placebo, a medicine that has no active medicine in it. Whic…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Hope Clin Res & Wellness, Conyers, Georgia

    Locations

    36 in total

    Run by

    Novo Nordisk A/S

    See if you can join NCT07745504 on ClinicalTrials.gov

11. A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity

    The purpose of the study is to find out if NNC0721-8060 is safe and how it works in people living with overweight or obesity.

    Stage

    Phase 1

    Ages

    18 to 55

    Site

    ICON Early Phase Services, LLC, Lenexa, Kansas

    Locations

    2 in total

    Run by

    Novo Nordisk A/S

    See if you can join NCT07767175 on ClinicalTrials.gov

12. New Heart Imaging Techniques to Evaluate Possible Heart Disease

    Background: - Imaging tests, such as magnetic resonance imaging (MRI), can provide information about heart and blood vessels. The tests let doctors can see the amount of blood vessel narrowing and vessel wall thickness. This information may help diagnose and treat heart disease and other conditions…

    Stage

    Not phased

    Ages

    18 to 100

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    See if you can join NCT01399385 on ClinicalTrials.gov

13. Sympathetic Transduction in Obesity-associated Hypertension (OB-HTN)

    The purpose of this study is to understand how the nervous system communicates to blood vessels to increase blood pressure during stress. The study will also investigate how hypertension and obesity influence the nervous system and vascular function. The study will involve measuring sympathetic ner…

    Stage

    EARLY_Phase 1

    Ages

    18 to 55

    Site

    University of Texas Southwestern Medical Center, Dallas, Texas

    Run by

    University of Texas Southwestern Medical Center

    See if you can join NCT04838678 on ClinicalTrials.gov

14. Ketogenic Diet and Diabetes Demonstration Project

    KDDP is a prospective, 12-month pilot study comparing the effects of a novel lifestyle program, the Ketogenic Diet and Diabetes Demonstration Project (KDDP) to those of the National Diabetes Prevention Program (NDDP). KDDP is modeled to mimic the delivery platform of NDPP with the exception that pa…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of New Mexico, Albuquerque, New Mexico

    Run by

    University of New Mexico

    See if you can join NCT06115265 on ClinicalTrials.gov

15. Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

    The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.

    Stage

    Phase 3

    Ages

    45 to 99

    Site

    Alliance For Multispecialty Research - Daphne, Daphne, Alabama

    Locations

    783 in total

    Run by

    Amgen

    See if you can join NCT07037433 on ClinicalTrials.gov

16. Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

    The primary objective of the study is to determine the effects of ribupatide (KAI-9531) subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Kailera Clinical Site, Anniston, Alabama

    Locations

    104 in total

    Run by

    Kailera

    See if you can join NCT07284875 on ClinicalTrials.gov

17. Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

    The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity and type 2 diabetes mellitus. Trial 20210182 is extension of trial 20210184 (NCT06858878).

    Stage

    Phase 3

    Ages

    18 to 99

    Site

    Gilbert Center for Family Medicine, Gilbert, Arizona

    Locations

    37 in total

    Run by

    Amgen

    See if you can join NCT07684144 on ClinicalTrials.gov

18. Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

    The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity or overweight. Trial 20250197 is an extension of trial 20210181 (NCT06858839).

    Stage

    Phase 3

    Ages

    18 to 99

    Site

    Pinnacle Research Group LLC, Anniston, Alabama

    Locations

    87 in total

    Run by

    Amgen

    See if you can join NCT07684235 on ClinicalTrials.gov

19. Effects of Obesity in the Aged

    The overall objective of this application is to investigate the effects of obesity on lung function, exercise tolerance, and DOE in older obese adults as compared with older adults without obesity, using a novel probe for mechanically unloading the thorax at rest and during exercise. The investigat…

    Stage

    Not phased

    Ages

    65 to 75

    Site

    Institute for Exercise and Environmental Medicine, UT Southwestern and Texas Health Resources, Dallas, Texas

    Run by

    University of Texas Southwestern Medical Center

    See if you can join NCT05028309 on ClinicalTrials.gov

20. Taxi ROADmAP (Realizing Optimization Around Diet And Physical Activity)

    The researchers will conduct 'Taxi ROADmAP (Realizing Optimization Around Diet And Physical activity)', which also utilizes MOST, and the same 4 obesity intervention components as in SANOS, but targets the overweight/obesity crisis in another at-risk, low socioeconomic status (SES) population, taxi…

    Stage

    Phase 2

    Ages

    21 and older

    Site

    Mexican Consulate's Ventanilla de Salud (VDS), New York, New York

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT05770570 on ClinicalTrials.gov

21. Physical and Behavioral Traits of Overweight and Obese Adults

    This study will describe the phenotype (physical and behavioral traits) of overweight and obese people. It will characterize the hormones, metabolism, food preferences, fitness and physical activity levels, sleep patterns and thought processes in people with and without weight problems. Genetic mat…

    Stage

    Not phased

    Ages

    18 to 100

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    See if you can join NCT00428987 on ClinicalTrials.gov

22. Heart Health Study in Washington D.C. to Develop a Community-Based Behavioral Weight Loss Intervention

    Background: - Past studies suggest that the best way to improve heart health in the Black community is through community-based programs. Researchers will partner with DC community leaders. They will collect information about the health and health needs of people in mostly Black churches in DC. They…

    Stage

    Not phased

    Ages

    19 to 85

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Heart, Lung, and Blood Institute (NHLBI)

    See if you can join NCT01927783 on ClinicalTrials.gov

23. Children s Growth and Behavior Study

    Background: - Studies show that many factors affect children's eating behavior and health. These include sleep, mood, thinking skills, and genetics. Studying children over time may identify children at higher risk for eating-related health concerns. Objective: - To understand how genes and environm…

    Stage

    Not phased

    Ages

    8 to 100

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

    See if you can join NCT02390765 on ClinicalTrials.gov

24. The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function

    Obesity is associated with increased cardiometabolic disease risk due, in part, to heightened chronic inflammation arising from adipose tissue. There are no current targeted therapies to prevent or reverse the chronic inflammation of obesity, and a better understanding of these inflammatory pathway…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Vanderbilt University Medical Center, Nashville, Tennessee

    Run by

    Vanderbilt University Medical Center

    See if you can join NCT05972564 on ClinicalTrials.gov

25. HealthyTogether: RCT of a Dyadic Weight Management Intervention

    Four in five Veterans have overweight or obesity. However, few eligible Veterans achieve meaningful weight loss in VA's national MOVE! Weight Management Program. Family and friends strongly influence a person's health behaviors and weight. Including a close family member or friend in weight managem…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora, Colorado

    Locations

    2 in total

    Run by

    VA Office of Research and Development

    See if you can join NCT06619041 on ClinicalTrials.gov